COVID-19
Solutions
RNA sequencing
HTPathwaySeq
HTTargetSeq
Digital PCR
Quantitative PCR
Custom primer design
Gene expression analysis
Mutation detection
Copy number analysis
SNP genotyping
Fusion gene detection
Antisense oligonucleotide screening
Sample preparation
Expertise
Biomarker discovery
Biomarker test development
Diagnostic services
Adoptive cell therapies
Non-coding RNA
Liquid biopsies
Clinical trials
Data analysis
Knowledge center
Publications
About
Contact
News & Events
News
Events
Why Biogazelle
Vision & mission
Management
Board of directors
Quality management
Our partners
Careers
COVID-19
Solutions
RNA sequencing
HTPathwaySeq
HTTargetSeq
Digital PCR
Quantitative PCR
Custom primer design
Gene expression analysis
Mutation detection
Copy number analysis
SNP genotyping
Fusion gene detection
Antisense oligonucleotide screening
Sample preparation
Expertise
Biomarker discovery
Biomarker test development
Diagnostic services
Adoptive cell therapies
Non-coding RNA
Liquid biopsies
Clinical trials
Data analysis
Knowledge center
Publications
About
Contact
News & Events
News
Events
Why Biogazelle
Vision & mission
Management
Board of directors
Quality management
Our partners
Careers
Search
Menu
COVID-19
Solutions
RNA sequencing
HTPathwaySeq
HTTargetSeq
Digital PCR
Quantitative PCR
Custom primer design
Gene expression analysis
Mutation detection
Copy number analysis
SNP genotyping
Fusion gene detection
Antisense oligonucleotide screening
Sample preparation
Expertise
Biomarker discovery
Biomarker test development
Diagnostic services
Adoptive cell therapies
Non-coding RNA
Liquid biopsies
Clinical trials
Data analysis
Knowledge center
Publications
About
Contact
News & Events
News
Events
Why Biogazelle
Vision & mission
Management
Board of directors
Quality management
Our partners
Careers
News
Recent updates and announcements
• Biogazelle lanceert speekseltest voor het opsporen van het COVID-19 virus op de werkvloer
• Biogazelle offering services to support COVID-19 vaccine & therapeutics development
• Biogazelle initiates large-scale testing for COVID-19 in Belgium
• Business continuity during the COVID-19 pandemic
• Biogazelle launches novel high-throughput RNA sequencing and data analysis services
• Biogazelle receives €499k Horizon 2020 funding to develop qPCR biomarker panels for multimorbidity associated with preterm birth
• Biogazelle CSO, Prof. Jo Vandesompele to present at ESHG 2019, Gothenburg
• From the archives: the idea behind the Biogazelle logo
• BARC and Biogazelle announce collaboration for advanced genetic testing in clinical trials
• Biogazelle offers unique mRNA sequencing on plasma
• Biogazelle offers mRNA sequencing on plasma – interview with CSO prof. Jo Vandesompele
• Nature publishes study on melanoma addiction to the long non-coding RNA SAMMSON, providing solid proof-of-concept for Biogazelle’s lncRNA targeting anti-cancer platform
• Exiqon’s antisense products are best in class in new comparative study
• RXi Pharmaceuticals demonstrates potent reduction of long non-coding RNAs in collaboration with Biogazelle
• Biogazelle and Ionis Pharmaceuticals evaluate long non-coding RNAs to identify and validate novel targets for anti-cancer drugs
• Biogazelle receives €1.1M IWT funding to develop lncRNA targeting cancer therapies
• Biogazelle offers unique microRNA sequencing on challenging samples
• Biogazelle strengthens its board of directors
• Biogazelle has established a quality management system and is ISO 17025 accredited for gene expression services
• UGent spin-off Biogazelle attracts new investors QBIC Arkiv Fund, Foundation Majoie and SOFI to finance growth
• Biogazelle serves as reference laboratory for Bio-Rad's droplet digital PCR system
• Belgian company Biogazelle develops lab products beyond industry standards
• Biogazelle presents a revolutionary qPCR based lncRNA profiling platform
